Future studies should be conducted in transgenic animal models of AD to assess whether fluoxetine or vortioxetine can prevent amyloid-induced depression and cognitive deficits by rescue of TGF-β1 signaling. The gene discussed is TGFB1; the disease is depressive symptom measurement.